Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance

Medicinal Research Reviews

Volumn 22, Issue 5, 2002, Pages 512-529

  Boumendjel, Ahcène ^a   Di Pietro, Attilio ^b   Dumontet, Charles ^c   Barron, Denis ^d  

^a Université Joseph Fourier   (France)

^b INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^c INSERM   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Flavonoids; Multidrug resistance (MDR); Nucleotide binding domain; P glycoprotein; Structure activity relationship (SAR)

Indexed keywords

3 HYDROXYFLAVONE; 7 HYDROXYFLAVONE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE DERIVATIVE; APIGENIN; CHALCONE; CHRYSIN; ETOPOSIDE; FLAVANONE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL; GALANGIN; GENISTEIN; GLUTATHIONE; GLYCOPROTEIN P; ISOFLAVONE; KAEMPFEROL; L 868276; LEUKOTRIENE; NARINGENIN; NATURAL PRODUCT; PROTEIN TYROSINE KINASE; QUERCETIN; SILIBININ; TAXIFOLIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; XANTHONE DERIVATIVE;

BINDING AFFINITY; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF 7; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHYTOCHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0036720280     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10015     Document Type: Review

References (103)

1. Biochemistry of multidrug resistance mediated by the multidrug transporter
2. Multiple drug resistance
3. In vivo characterization of the drug resistance profile of the major ABC transporters and other components of the yeast pleiotropic drug resistance
4. Multidrug resistance transporters and modulation
5. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
6. Multidrug-resistance transporters
7. A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants
8. A family of drug transporters: The multidrug resistance -associated proteins
9. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters
10. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
11. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins
12. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance
13. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase
14. Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP 1
15. The human multidrug resistance-associated protein (MRP) gene family: From biological function to drug molecular design
16. The multidrug resistance protein family
17. Membrane topology of a cysteine-less mutant of human P-glycoprotein
18. Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence
19. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold
20. Traffic ATPases: A superfamily of transport proteins operating from Escherichia coli to humans
21. Effects of phosphorylation of P-glycoprotein on multidrug resistance
22. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis
23. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells
24. Interaction of bioactive hydrophobic peptides with the human multidrug transporter
25. Kinetic analysis of the mechanism of action of the multidrug transporter
26. Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance
27. Expression of multidrug-resistance gene in human tumors and tissues
28. P-glycoprotein in human sarcoma: Evidence for multidrug resistance
29. Mechanism of multidrug resistance
30. The biochemistry of P-glycoprotein-mediated multidrug resistance
31. P-glycoprotein: Multidrug-resistance and a superfamily of membrane-associated transport proteins
32. The clinical relevance of multidrug resistance
33. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
34. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations
35. Clinical trials of agents that reverse multidrug resistance
36. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone
37. P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid
38. Steroid transport, accumulation and anatgonism of P-glycoprotein in multidrug-resistant cells
39. Reversal of multidrug resistance by RU486
40. Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site
41. The antiprogestatin drug RU486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function
42. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer
43. Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe
44. Overexpression and purification of the carboxyl-terminal nucleotide binding domain from mouse P-glycoprotein. Strategic location of a tryptophan residue
45. Flavonoids: A class of modulators with bifunctional interactions at ATP and steroid-binding sites of the mouse P-glycoprotein
46. Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein: Overexpression, purification and role of cysteine 430
47. Advances in flavonoid research since 1992
48. Review of the biology of quercetin and related bioflavonoids
49. Scavenger and antioxidant properties of ten synthetic flavones
50. Pharmacokinetics and antitumor activity of LM985 in mice bearing transplantable adenocarcinomas of the colon
51. Cytotoxic flavone from Scoparia dulcis L.
52. Cytotoxicities of some flavonoid analogues
53. Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents
54. Effects of flavonoids on the growth and cell cycle of cancer cells
55. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes
56. Aromatase inhibition by flavonoids
57. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol
58. Protein kinase C inhibition by plant flavonoids
59. v-src
60. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
61. Mechanistic evaluation of new plant-derived compounds that inhibit HIV-1 reverse transcriptase
62. Antiviral activity of flavones and flavans
63. Flavonol-stimulated efflux of 7,12-dimethylbenz(a)-anthracene in multidrug-resistant breast cancer cells
64. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells: Activation of P-glycoprotein as a putative mechanism
65. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer
66. Quercitin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target
67. Effect of quercitin on Hoechest 33342 transport by purified and reconstituted P-glycoprotein
68. In vitro evaluation of newly developed chalcone analogues in human cancer cells
69. Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells
70. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance
71. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumor cells
72. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein
73. Inhibition of drug transport by genistein in multidrug-resistant expressing P-glycoprotein
74. Halogenated chalcones with high-affinity binding to P-glycoprotein: Potential modulators of multidrug resistance
75. H-bond contribution to octanol-water partition coefficients of polar compounds
76. Synthesis and biological activity of 4-alkoxy chalcones: Potential hydrophobic modulators of P-glycoprotein-mediated multidrug resistance
77. Organolithium mediated synthesis of prenylchalcones as potential inhibitors of chemoresistance
78. B-ring substituted 5,7-dihydroxyflavonols with high-affinity binding to P-glycoprotein responsible for cell multidrug resistance
79. The structure of silybin (silybum substance E6), the first flavonolignan
80. Structure of silybin. Degradative experiments
81. Structure of silybin. Synthesis of dehydrosilybin pentamethyl ether and related compounds
82. Structure of silybin. Synthetic studies
83. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein
84. Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump: Structure-activity relationships
85. Synthesis of 8-C-(1,1-dimethylallyl)-flavones and 3-methylflavonols
86. Rearrangement of 5-O-prenylflavones: A regioselective access to 6-C-(1,1-dimethylallyl)- and 8-C-(3,3-dimethylallyl)flavones
87. C-isoprenylation of flavonoids enhances affinity toward P-glycoprotein and modulation of cancer cell chemoresistance
88. Selective inhibitors of monoamine oxidase A and B: Biochemical, pharmacological and clinical properties
89. Prenylated xanthones as potential P-glycoproetin modulators
90. Flavonoid-related modulators of multidrug resistance: Synthesis, pharmacological activity, and structure-activity relationships
91. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemia cells
92. +-ATPase: Aspects of the structure-activity relationship and action mechanism
93. 2+ pump. Kinetics and structure-function relationships
94. Inhibition of rat liver cyclic AMP-dependent protein kinase by flavonoids
95. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships
96. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases
97. Genistein, a specific inhibitor of tyrosine-specific protein kinases
98. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: Evidence for distinct drug interaction domains on topoisomerase II
99. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
100. Crystal structure of the Src family tyrosine kinase Hck
101. Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse P-glycoprotein: Structure-activity relationships for flavonoid binding
102. Structure-activity relationships of multidrug resistance reversers